Interchangeability, early meetings, review timelines and access are among the key priorities that have been set out by US biosimilars industry stakeholders as the Biosimilar User Fee Act approaches its second reauthorization.
Interchangeability, Meetings And Access Among BsUFA III Priorities
Stakeholders Offer Specific Recommendations On US Biosimilar User Fee Program
Industry stakeholders have offered their views on key priorities for the BsUFA biosimilars user-fee program ahead of its reauthorization.
More from Biosimilars
More from Products
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
• By
In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.
• By
Generics Bulletin reviews global regulatory developments across the world.